Editas Medicine Inc (EDIT)
5.625
-0.26
(-4.50%)
USD |
NASDAQ |
May 17, 16:00
5.625
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Enterprise Value: 166.01M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 166.01M |
| May 16, 2024 | 188.21M |
| May 15, 2024 | 197.26M |
| May 14, 2024 | 170.94M |
| May 13, 2024 | 173.41M |
| May 10, 2024 | 141.34M |
| May 09, 2024 | 161.07M |
| May 08, 2024 | 117.90M |
| May 07, 2024 | 170.94M |
| May 06, 2024 | 169.30M |
| May 03, 2024 | 170.12M |
| May 02, 2024 | 165.99M |
| May 01, 2024 | 153.65M |
| April 30, 2024 | 132.27M |
| April 29, 2024 | 145.43M |
| April 26, 2024 | 141.32M |
| April 25, 2024 | 133.09M |
| April 24, 2024 | 143.78M |
| April 23, 2024 | 152.83M |
| April 22, 2024 | 164.34M |
| April 19, 2024 | 155.30M |
| April 18, 2024 | 160.23M |
| April 17, 2024 | 165.17M |
| April 16, 2024 | 184.90M |
| April 15, 2024 | 203.82M |
| Date | Value |
|---|---|
| April 12, 2024 | 214.51M |
| April 11, 2024 | 244.93M |
| April 10, 2024 | 249.05M |
| April 09, 2024 | 280.29M |
| April 08, 2024 | 256.45M |
| April 05, 2024 | 256.45M |
| April 04, 2024 | 263.85M |
| April 03, 2024 | 267.96M |
| April 02, 2024 | 268.78M |
| April 01, 2024 | 302.50M |
| March 31, 2024 | 314.01M |
| March 28, 2024 | 283.95M |
| March 27, 2024 | 285.58M |
| March 26, 2024 | 267.59M |
| March 25, 2024 | 279.04M |
| March 22, 2024 | 288.04M |
| March 21, 2024 | 317.49M |
| March 20, 2024 | 324.86M |
| March 19, 2024 | 310.95M |
| March 18, 2024 | 308.49M |
| March 15, 2024 | 342.04M |
| March 14, 2024 | 343.67M |
| March 13, 2024 | 379.67M |
| March 12, 2024 | 381.31M |
| March 11, 2024 | 413.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
117.90M
Minimum
May 08 2024
5.265B
Maximum
Jan 08 2021
1.079B
Average
766.98M
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 104.72B |
| Bristol-Myers Squibb Co | 135.32B |
| Regeneron Pharmaceuticals Inc | 99.70B |
| Cabaletta Bio Inc | 372.37M |
| Oragenics Inc | 8.862M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.95M |
| Revenue (Quarterly) | 1.135M |
| Total Expenses (Quarterly) | 68.13M |
| EPS Diluted (Quarterly) | -0.76 |
| Profit Margin (Quarterly) | -5.46K% |
| Earnings Yield | -37.37% |
| Normalized Earnings Yield | -37.37 |